Institutional
Foresite Capital Management V, LLC
CIK 0001792206
$271.0M
Reported AUM
9
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · Foresite Capital Management V, LLC · Q1 2026
AI · grounded in 13F
Foresite Capital Management V, LLC closed its position in Natera, Inc. NTRA, reducing its exposure by $15.4M. The fund established new positions in Eikon Therapeutics, Inc. EIKN for $13.9M, Pharvaris N.V. for $5.4M, and Nurix Therapeutics, Inc. NRIX for $4.1M. Additionally, the fund increased its stake in Hims & Hers Health, Inc. HIMS by 170.2%.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALMS | ALUMIS INC. | $27.45 | 4.06% | 543.95% | 116.22% | $129.9M | 47.94% | — | HELD |
| 2 | CGON | CG Oncology, Inc. | $67.62 | -2.17% | 164.95% | 55.91% | $68.0M | 25.08% | — | HELD |
| 3 | IRON | Disc Medicine, Inc. | $74.16 | 0.67% | 24.93% | -50.09% | $23.9M | 8.83% | — | HELD |
| 4 | HIMS | Hims & Hers Health, Inc. | $25.00 | -0.01% | -60.03% | 217.26% | $15.3M | 5.65% | — | HELD |
| 5 | EIKN | Eikon Therapeutics, Inc. | $9.11 | 1.11% | -37.86% | -14.84% | $14.0M | 5.15% | — | HELD |
| 6 | LYEL | Lyell Immunopharma, Inc. | $13.00 | 0.23% | 17.70% | -95.89% | $9.6M | 3.53% | — | HELD |
| 7 | PHVS | Pharvaris N.V. | $32.96 | 1.04% | 66.05% | 64.49% | $5.5M | 2.02% | — | HELD |
| 8 | NRIX | Nurix Therapeutics, Inc. | $23.68 | 0.32% | 113.18% | -26.89% | $4.1M | 1.52% | — | HELD |
| 9 | MAZE | Maze Therapeutics, Inc. | $28.10 | 3.04% | 83.02% | 122.98% | $773K | 0.29% | — | HELD |
Source: SEC EDGAR · accession 0001104659-26-062464. 13F discloses long positions only — shorts, foreign equities, and options are excluded.